Company Culture: How to Retain Creativity as the Company Matures
#WESTinnovation

Abbie Celniker, Ph.D is the CEO of Eleven Bioptherapeutics, a publically traded biopharmaceutical company focused on engineering and developing innovative protein-based therapies to treat ocular diseases.  Dr. Celniker has been in the biotechnology and pharmaceutical industry for over 25 years where she has worked in small and mid-sized biotechnology companies as well as mid-sized and large pharmaceutical companies  Prior to Eleven, Abbie was head of Translational Medicine at Alexion Pharmacueticals by way of  the acquisition of Taligen Therapeutics where she was the President and CEO.  Prior to joining Taligen, Dr. Celniker was  the Global Head of Novartis Biologics where she was responsible the oversight of the discovery and development of the Novartis biologics pipeline.  Dr. Celniker has also been the Global Head of the  Program Office for the Novartis Institutes for Biomedical Research (NIBR)  where she was responsible for the global integration and oversight of the Novartis Discovery Portfolio.  In a previous role at Millennium Pharmaceuticals, Dr. Celniker led the pipeline portfolio review committee and headed Development Project Management and Pharmaceutical Sciences.    Prior to Millennium, Dr. Celniker was at Wyeth, where she was assistant vice president for predevelopment and biopharmaceutical core technologies. She has previously held positions at Genetics Institute, Genentech Inc. and the University of Arizona Cancer Center. Dr. Celniker is a member of the MassBio board of directors, is the chair of the board of directors of ImaginAb, and a member of the scientific advisory board for Adimab.  Dr. Celniker has a bachelor's degree in biology from the University of California at San Diego and earned her Ph.D. in molecular biology at the University of Arizona. 

John Maraganore, CEO of Alnylam Pharmaceuticals
Since 2002, John Maraganore has served as the CEO and a Director of Alnylam.  Prior to Alnylam he served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc. As Senior Vice President, Strategic Product Development for Millennium, he was responsible for the company’s product franchises in Oncology and Cardiovascular, Inflammatory and Metabolic Diseases.  He was previously Vice President, Strategic Planning and M&A and prior to that he was General Manager of Millennium BioTherapeutics, Inc., a former subsidiary of Millennium. Before Millennium he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. At Biogen, Dr. Maraganore invented and led the discovery and development of Angiomax^TM (bivalirudin for injection, formerly Hirulog^TM) currently marketed by The Medicines Company. Prior to Biogen, Dr. Maraganore was a scientist at ZymoGenetics, Inc., and the Upjohn Company. Dr. Maraganore received his M.S. and Ph.D. in biochemistry and molecular biology at the University of Chicago.  Dr. Maraganore is a Director for Agios Pharmaceuticals and bluebird bio. He also serves as a Venture Partner with Third Rock Ventures. Dr. Maraganore is a member of the Biotechnology Industry Organization (BIO) Board and the BIO Executive Committee, and serves as the chair of the Emerging Company Section and as co-chair of the Regulatory Environment Committee.

Adelene Perkins, CEO of Infinity Pharmaceuticals, Inc
Adelene Q. Perkins has served as Infinity's President and Chief Executive Officer since 2009. Additionally, Ms. Perkins currently serves as the Chair of the Board of Directors at Infinity. Ms. Perkins first joined Infinity as Chief Business Officer in 2002 and then served as President and Chief Business Officer of Infinity from 2008-2009. Since joining Infinity, she has played an integral role in developing Infinity's business strategy, leading the company in its transition from a platform to a product-based organization. She has also been the principal figure in structuring, executing and managing all of Infinity's innovative strategic relationships.  Ms. Perkins has more than 25 years of international business and corporate strategy experience in the biopharmaceutical industry, focused on licensing and business development, strategic finance, product life cycle management, and leading high-caliber, cross-functional teams. Ms. Perkins joined Infinity from TransForm Pharmaceuticals where she served as vice president of business and corporate development and an early member of the management team that built the company prior to its acquisition by J&J. From 1992-1999, she was vice president of emerging businesses and the cofounder and general manager of the DiscoverEaseT business unit at Genetics Institute, now part of Pfizer. She also formed and served as chief executive officer of MetaMorphix, a joint venture between Genetics Institute and Johns Hopkins University. From 1985-1992, Ms. Perkins worked at Bain & Company, an international strategy consulting firm, where she provided strategic and operational advice to clients in the healthcare industry.  Ms. Perkins received her M.B.A. from Harvard Business School and her B.S. in chemical engineering from Villanova University. She is on the Board of Project Hope and the Villanova University College of Engineering Advisory Board.